Results 191 to 200 of about 33,286 (224)

Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial

Lancet, The, 2023
Tamar Murray, John R Mascola, Aurélie Ploquin   +2 more
exaly  

Generation of Biologically Contained Marburg Virus

Wild-type Marburg virus (MARV) can only be handled in biosafety level 4 facilities. By removing an essential gene from the virus genome, deficient virus particles can be generated that are only capable of replication if the missing gene product is provided in trans.
Bert, Vanmechelen, Joren, Stroobants, Kurt, Vermeire, Piet, Maes   +3 more
openaire   +2 more sources

Cervical cancer prevention and control in women living with human immunodeficiency virus

Ca-A Cancer Journal for Clinicians, 2021
Philip E Castle, Vikrant V Sahasrabuddhe
exaly  

Marburg Virus

2016
openaire   +2 more sources

Filovirus pathogenesis and immune evasion: insights from Ebola virus and Marburg virus

Nature Reviews Microbiology, 2015
Ilhem Messaoudi, Gaya K Amarasinghe, Christopher F Basler   +2 more
exaly  

Post-exposure treatments for Ebola and Marburg virus infections

Nature Reviews Drug Discovery, 2018
Robert W Cross, Chad E Mire, Heinrich Feldmann   +2 more
exaly  

Marburg Virus Disease

1977
HERTA WULFF, J. LYLE CONRAD
openaire   +1 more source

Developing a vaccine against Marburg virus disease

Lancet, The, 2023
exaly  

Marburg Virus

1972
openaire   +1 more source

Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial

Lancet, The, 2015
Zonghui Hu, Leigh Anne Eller, John R Mascola   +2 more
exaly